Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PKPD > exam 4 > Flashcards

exam 4 Flashcards

1
Q

in many cases, they disposition of therapeutic monoconal antibody drugs in non-linear due to target-mediated elimination. For a monoclonal antibody demonstrating this behavior, saturation of the target-mediated pathway would be expected to

A

lead to a decrease in CL of the monoclonal antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

adminstration of high doses of IgG, as in IV IG therapy, may be expected to

A

increase the clearance of therapeutic IgG monoclonal antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

general expectations for antibody pk include

A
  • good absorption following sq dosing
  • good absorption following IM dosing
  • bi-exponential disposition
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is INCORRECT regarding anti-adalimumab abx (AAA)

A

-AAA develop in ~80% of pts receiving long-term therapy - AAA are likely to increase the clearance of ALL therapeutic monoclonal antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

the major organ producing EOP is

A

kidneys

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

F of rHuEOP following subq admins

A

increases with dose

IV= decreases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

clinical markers for EPO efficiency

A
  • hematocrit
  • RBC count
  • hemoglobin concentration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

some facts about warfarin

A
  • S-warfarin is primarily metabolized by CYP2c9
  • warfarin is highly protein bound, up to 99% mostly by albumin
  • warfarin is rapidly & well absorbed in the GI tract
  • R-warfarin exhibits a longer half-life than S-warfarin
  • anticoagulation is not achieved until 4-5 days after initiation of warfarin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is TMDD not a concern for the clinical dosing and monitoring of warfarin therapy?

A

-kinetics are nonlinear on first-dose but becomes dose-proportional on multiple dosing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

factors that can affect the anticoagulant effects & dosing of warfarin

A
  • co-admin with fluconazole
  • genetic variation in the CYP2c9 gene
  • genetic variation in the VCORC1 gene
  • co-admin with rifampin
  • warfarin cl decreasing with age
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

new England journal things (2)

A
  • only one of the studies showed a statical difference supporting genotype-based warfarin dosing
  • these trails addressed the initiation of warfarin therapy and not maintenance dosing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

requirements for bayesian therapy

A
  • a prior population pk/pd model
  • feedback measurements of INR
  • computer software featuring a bayesian algorithm
  • the prescribed regimen and pt characteristics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

figure with distribution pattern of S/R warfarin

A

-S-warfarin cl follows a bimodal log-normal distribution pattern

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

figure with pk of anti-human CD3 antibody in a pt at different occasions (1-10th day dosing lines)

A
  • the antibody pk demonstrates notable inter-occasion variability
  • the antibody pk demonstrates notable within-subject variability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

kaplan-meier plot for overall survival of pts with primary CNS lymphoma

A
  • pts with higher AUC values have longer survival time
  • less than 25% of pts with lower AUC values survived following 5 years of MTX tx
  • AUC vlue is a strong indicator for the efficiacy of MTX
  • measurements of AUC value is a good therapeutic practice for the treatment of primary CNS lymphoma ptts with MTX
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

which of the following is a routinely used method for a priori determination of the dosage for chemotherapeutic drugs

A
  • dose determination based on renal or liver function
  • dose determination based on pts propensity for toxicity
  • dose determination based on pts pharmacogenetics
  • dose determination based on BSA or BW
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

q LSM can still be used if it is not prospectively validated using the same

A
  • cancer indication

- brand names

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what controls the terminal half-life of EPO following subq admin

A

absorption from the subq site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

the major factor contributing to the clinical efficacy of EPO is

A

clearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what is NOT required for bayesian adaptive control of individual pt warfarin regimens?

A

feedback measurements of warfarin plasma concentrations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what is correct about anti-digoxin immune fab

A
  • ADF is an example of an antibody that is used for immunotoxicotherapy
  • ADF is NOT protected bt FcRn, the fc-receptor of the neonate
  • ADF is in the same category of antibody application as infliximab & bevacizumab
22
Q

response regarding anti-adalimumab antibodies (AAA)

A

in general, pts who develop high titiers of AAA demonstrate low exposures to adalimumab

23
Q

figure with platimun AUC

A

-paclitaxel leads to a PD DDI with carboplatin that leads to decreased toxicity of carboplatin

24
Q

what is the most common distribution pattern observed for the pk parameters while characterizing their inter-individual variability?

A

log-normal

25
Q

what is the limit of BSA value that one could use to a priori calculate the dose of an anticancer agents for obese pts

A

2.2 m^2

26
Q

which of the therapies is given prior to the surgical procedure to shrink tumor burden

A

neoadjuvant therapy

27
Q

what is NOT a routinly used method for a priori determination of the dosage for chemotherapeutic drugs

A

dose determination based on pts tumor size and tumor growth rate

28
Q

based on the duration-free survival vs time graph provided for methotrexate, which of the following PK matrix best correlates with the efficacy of MTX

A

Cmax

29
Q

graph with unbound concentration of warfarin associated with similiar degree of anticoagulation response in a group of 97 pts

A

pharmacodynamic variability

30
Q

inter-individual variability in the PD of a drug stems from

A
  • genetic mutation in the receptors affected by the drug
  • environmental factors
  • concurrent drugs and diseases
31
Q

2018 nobel prizes in med was awarded for

A

immunotherapy

32
Q

inter-individual variability in the PD of a drug stems from

A
  • genetic mutations in the receptors affected by the drug
  • environmental factors
  • concurrent drugs and diseases
33
Q

the 2018 nobel prizes in medicine was awarded for which type of cancer tx

A

immunotherapy

34
Q

general expectations for antibody pk includes

A
  • good absorption following subq dosing
  • good absorption following intra-muscular dosing
  • bi-exponential disposition
  • small volume of distribution (3-9L)
35
Q

Fc-receptor of the neonate fact things

A
  • FcRn is also known as the brambell receptor

- FcRn protects IgG antibodies from intracellular catabolism

36
Q

select the most appropriate response regarding protein pk

A

anti-drug antibodies typically lead to an increase in the rate of elimination of the therapeutic protein (drug)

37
Q

select the most appropriate response regarding anti-adalimumuab antibodies (AAA)

A
  • AAA develops in over 20% of pts recieving long-term therapy with adalimumab
  • pts who develop high titers of AAA demonstrate low concentration of adalimumab
  • pts who develop AAA are more likely to discontinue adalimumuab therapy due to tx failure
38
Q

drug-drug interactions involving antibody drugs include:

A
  • the effects of high-dose IgG therapy on monoclonal antibody clearance
  • the effects of immunosuppressive therapy on the development of ADA and on monoclonal antibody cl
  • the effects of bevacizumab on monoclonal antibody distribution to solid tumors
39
Q

which of the following clearance mechanisms does contribute to nonlinear erythropoietin pk

A

receptor mediated endocytosis

40
Q

which is the most relevant clinical marker for EPO efficacy

A

hemoglobin level

41
Q

if the same dose of EPO is administered repeatedly to a pt, then the hemoglobin response:

A

is higher for sc injection than fir IV injections

42
Q

adminstration of high doses of IgG may be expected to:

A
  • increase the clearance of therapeutic IgG monoclonal antibodies
  • increase the clearance of endogenous IgG antibodies
43
Q

four mechanistic categories of therapeutic application were presented for monoclonal antibody drugs,

A
  • drug delivery
  • elimination of cells
  • alteration of cell function
  • immunotoxiciotherapy
44
Q

more Fcr receptor of the neonates facts

A
  • FcRn may become saturated in the presence of high concentrations of IgG
  • FcRn protects albumin from intracellular catabolism
  • FcRn demonstrates little to no affinity for IgG at pH 7.4
45
Q

warfarin exhibits target-mediated drug disposition meaning:

A

drug binding to the target influences its pharmacokinetics

46
Q

what is true regarding target-mediated drug disposition of small molecule drugs?

A
  • the first dose shows linear kinetics

- the distribution phase for low doses is steep as compared to high doses

47
Q

inter-ndividual variability in the PD of a drug stems from

A
  • genetic mutation in the receptors affected by the drug
  • environmental factors
  • concurrent drugs and diseases
48
Q

for anticancer agents which of the following PK matrix has been used to establish a correlation with efficacy/toxicity?

A
  • AUC
  • Css
  • Cmax
  • time above a threshold concentrations
49
Q

for which drugs is the leucovorin rescue therapy used?

A

methotrexate

50
Q

a LMS can only be applied it it has been prospectively validated using the same:

A
  • anticancer agent
  • dose
  • administration schedule
  • duration of infusion

PKPD (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions